Physician
Hematology
Dr. Alan P. Lyss, MD
|
|
Give Review
Alan Lyss practices Hematology. He went to medical school at Washington University School of Medicine in St. Louis. He over the years received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Top MD". Alan Lyss is a published doctor as well. He has 46 publications published. The latest was: Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). He accepts all Medicare patients.
Publications
- The changing face of research in community practice.
- A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: North Central Cancer...
- The clinical research team.
- Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast Cancer.
- Accrual to National Cancer Institute-sponsored non-small-cell lung Cancer trials: insights and contributions from the CCOP program.
- Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast Cancer in SWOG-8897.
- Nitric oxide synthase variants and disease-free survival among treated and untreated breast Cancer patients in a Southwest Oncology Group clinical trial.
- Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung Cancer.
- Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for ...
- Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung Cancer: a limited-access study--CALGB 9534.
- Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast Cancer.
- Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
- Novel doublets in extensive-stage small-cell lung Cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).
- Long-term safety of oral transmucosal fentanyl citrate for breakthrough Cancer pain.
- High-dose paclitaxel plus G-CSF for Malignant mesothelioma: CALGB phase II study 9234.
- Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in Cancer patients: a controlled dose titration study.
- Amonafide: An active agent in the treatment of previously untreated advanced breast Cancer--a Cancer and leukemia group B study (CALGB 8642).
- Strategies for limiting the side effects of Cancer pain therapy.
- Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.
- Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast Cancer. The Cancer and Leukemia Group B.
- A phase II trial of gallium nitrate in advanced previously untreated colorectal Cancer.
- Adenocarcinoid tumor of the colon arising in preexisting ulcerative colitis.
- Fc and C3 receptors induced by herpes simplex virus on cultured human endothelial cells.
- Ph1-positive acute Leukemia with a 17q;21q translocation.
- Chemotherapy of advanced breast Cancer. A general survey.
- Presence of complement-fixing anti-endothelial cell antibodies in Systemic lupus erythematosus.
- Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.
- Sweet's syndrome in association with solid Tumors.
- Systemic treatment for prostate Cancer.
- Appendiceal malignancies.
- Metastatic thyroid adenoCarcinoma presenting as exophthalmos.
- Treatment of disseminated non-small cell lung Cancer. Guidelines for the practicing physician.
- Vindesine and mitomycin C in metastatic breast Cancer. A Southeastern Cancer Study Group Trial.
- Management of soft tissue sarcomas of the extremities.
- Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic Breast carcinoma.
- A simple method to estimate the initial dose of gentamicin.
- Evaluation of an implantable venous access System in a general oncology population.
- Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung Cancer: a randomized phase II study of the Cancer and leukemia gro...
- Carboplatin in non-small cell lung Cancer: an update on the Cancer and Leukemia Group B experience.
- Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung Cancer. A phase II trial of the Cancer and Leukemia Group B.
- Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats.
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive brea...
- Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast Cancer.
- 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung Cancer: analysis of Cancer and Leukemia Group B study 39808.
- ReCAP: Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool.
Schools
Washington University St Louis
Ohio State University Hospital
Hospital Of The University Of Pennsylvania
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Top MD
Education
-
University of Pennsylvania Health System -
Ohio State University Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
St. Luke's Hospital
Drug Facts
| NPI NUMBER | 1013920651 | |
| NPPES Provider LastName | LYSS | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 631312329 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1311.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 78.0 | |
| Percent Opioid Claims | 5.95 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013920651 |
| Last Name Of The Provider | LYSS |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
|
Dr. Scot G. Hickman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Camille N. Abboud, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Ley, MD |
|
|
Dr. Tudung T. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Tomasson, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. James G. Glauber, MD |
|
|
Dr. Jennifer J. O'Brien, MD |
|
|
Dr. Ali A. Mohamed, MD |
|
|
Dr. Terrence N. Wong, MD |